Abstract | BACKGROUND: METHODS AND RESULTS: The ADANCE [ Apixaban Versus Dual-antiplatelet Therapy ( Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events] study is a randomized, double-blind clinical trial with a target enrollment of 5,500 patients. A 21-day regimen of apixaban or of clopidogrel with aspirin followed by clopidogrel on days 22 through 90 will be administered to randomized participants with acute TIA or minor ischemic stroke. The primary efficacy endpoint is the percentage of patients with any new stroke (ischemic or hemorrhage), including fatal stroke, at day 21. Study visits will be performed on the day of randomization, and at days 7, 22, and 90. DISCUSSION:
|
Authors | Fang Yang, Hui Lei, Wenrui Jiang, Wen Jiang, Junliang Han, Gang Zhao |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 34
Issue 11
Pg. 755-61
(Nov 2014)
ISSN: 1179-1918 [Electronic] New Zealand |
PMID | 25200142
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Pyrazoles
- Pyridones
- apixaban
- Clopidogrel
- Ticlopidine
- Aspirin
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aspirin
(administration & dosage, therapeutic use)
- Clopidogrel
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Endpoint Determination
- Female
- Humans
- Male
- Platelet Aggregation Inhibitors
(administration & dosage, therapeutic use)
- Pyrazoles
(administration & dosage, therapeutic use)
- Pyridones
(administration & dosage, therapeutic use)
- Stroke
(drug therapy)
- Ticlopidine
(administration & dosage, analogs & derivatives, therapeutic use)
- Time Factors
- Treatment Outcome
- Young Adult
|